# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Dexter Susan			2. Issuer Name and Ticker or Trading Symbol <u>Sonnet BioTherapeutics Holdings, Inc.</u> [SONN ]	(Check al	onship of Reporting Person(s II applicable) Director	i) to Issuer 10% Owner
(Last) (First) (Middle) 100 OVERLOOK CENTER, SUITE 102			3. Date of Earliest Transaction (Month/Day/Year) 01/07/2023	I X	Officer (give title below) Chief Technical C	Other (specify below) Officer
(Street) PRINCETON, (City)	NJ (State)	08540 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individ X	ual or Joint/Group Filing (Ch Form filed by One Reportin Form filed by More than Or	g Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)
Common Stock	01/07/2023		D		14,627(1)	D	(1)	9,040(2)(3)	D	
Common Stock	01/07/2023		A		14,627(1)	A	(1)	23,667(3)	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(*.9.	, p,		,		, p			,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Num Derivat Securit Acquin or Disp (D) (Ins and 5)	tive ties ed (A) bosed of	6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and A Securities U Derivative S (Instr. 3 and	nderlying ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e Ownership of In s Form: Bene ally Direct (D) Own or Indirect (I) (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		

## Explanation of Responses:

1. On December 14, 2022, the Reporting Person was granted 14,627 restricted stock units to be settled in shares of common stock, par value \$0.0001. On January 7, 2023, the 14,627 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 14,627 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date.

2. A Form 4 that was filed by the Reporting Person on December 22, 2022, incorrectly included amounts in Column 5 of Table I that did not reflect a 14:1 reverse stock split of the Issuer's common stock, effective September 16, 2022.

3. Includes unvested restricted stock units.

/s/ John Harry Cross III, power of 02/17/2023

\*\* Signature of Reporting Person Date

attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5